[1]
|
Westphal, J.F. and Brogard, J.M. (1997) Drug Administration in Chronic Liver Disease. Drug Safety, 17, 47-73. https://doi.org/10.2165/00002018-199717010-00004
|
[2]
|
Franz, C.C., Hildbrand, C., Born, C., Egger, S., Rätz Bravo, A.E. and Krähenbühl, S. (2013) Dose Adjustment in Patients with Liver Cirrhosis: Impact on Adverse Drug Reactions and Hospitalizations. European Journal of Clinical Pharmacology, 69, 1565-1573. https://doi.org/10.1007/s00228-013-1502-z
|
[3]
|
Lewis, J.H. and Stine, J.G. (2013) Review Article: Prescribing Medications in Patients with Cirrhosis—A Practical Guide. Alimentary Pharmacology & Therapeutics, 37, 1132-1156. https://doi.org/10.1111/apt.12324
|
[4]
|
Edginton, A.N. and Willmann, S. (2008) Physiology-Based Simulations of a Pathological Condition: Prediction of Pharmacokinetics in Patients with Liver Cirrhosis. Clinical Pharmacokinetics, 47, 743-752. https://doi.org/10.2165/00003088-200847110-00005
|
[5]
|
Trevisani, F., Merli, M., Savelli, F., Valeriano, V., Zambruni, A., Riggio, O., et al. (2003) QT Interval in Patients with Non-Cirrhotic Portal Hypertension and Cirrhotic Patients Treated with a Transjugular Intrahepatic Portosystemic Shunt. Journal of Hepatology, 38, 461-467. https://doi.org/10.1016/S0168-8278(03)00057-6
|
[6]
|
Bal, J.S. and Thuluvath, P.J. (2003) Prolongation of QTc Interval: Relationship with Etiology and Severity of the Liver Disease, Mortality, and Liver Transplantation. Liver International: Official Journal of the International Association for the Study of the Liver, 23, 243-248. https://doi.org/10.1034/j.1600-0676.2003.00833.x
|
[7]
|
Frye, R.F., Zgheib, N.K., Matzke, G.R., Chaves-Gnecco, D., Rabinovitz, M., Shaikh, O.S., et al. (2006) Liver Disease Selectively Modulates Cytochrome P450-Mediated Metabolism. Clinical Pharmacology & Therapeutics, 80, 235-245. https://doi.org/10.1016/j.clpt.2006.05.006
|
[8]
|
Garcia-Martinez, R., Caraceni, P., Bernardi, M., Gines, P., Arroyo, V. and Jalan, R. (2013) Albumin: The Pathophysiologic Basis of Its Role in the Treatment of Cirrhosis and Its Complications. Hepatology (Baltimore, Md.), 58, 1836-1846. https://doi.org/10.1002/hep.26338
|
[9]
|
Ulldemolins, M., Roberts, J.A., Rello, J., Paterson, D.L. and Lipman, J. (2011) The Effects of Hypoalbuminemia on Optimizing Antibacterial Dosing in Critically Ill Patients. Clinical Pharmacokinetics, 50, 99-110. https://doi.org/10.2165/11539220-000000000-00000
|
[10]
|
Delcò, F., Tchambaz, L., Schlienger, R., Drewe, J. and Krähenbühl, S. (2005) Dose Adjustment in Patients with Liver Disease. Drug Safety, 28, 529-545. https://doi.org/10.2165/00002018-200528060-00005
|
[11]
|
Xia, M.-F., Bian, H. and Gao, X. (2019) NAFLD, and Diabetes: Two Sides of the Same Coin? The Rationale for Gene-Based Personalized NAFLD Treatment. Frontiers in Pharmacology, 10, 877. https://doi.org/10.3389/fphar.2019.00877
|
[12]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Non-Alcoholic Fatty Liver Disease-Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
|
[13]
|
Adams, L.A., Lymp, J.F., St Sauver, J., Sanderson, S.O., Lindor, K.D., Feldstein, A., et al. (2005) The Natural History of Non-Alcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology, 129, 113-121. https://doi.org/10.1053/j.gastro.2005.04.014
|
[14]
|
Portillo-Sanchez, P., Bril, F., Maximos, M., Lomonaco, R., Biemacki, D., Orsak, B., et al. (2015) High Prevalence of Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels. The Journal of Clinical Endocrinology and Metabolism, 100, 2231-2238. https://doi.org/10.1210/jc.2015-1966
|
[15]
|
Bazick, J., Donithan, M., Neuschwander-Tetri, B.A., Kleiner, D., Brunt, E.M., Wilson, L., et al. (2015) Clinical Model for NASH and Advanced Fibrosis in Adult Patients with Diabetes and NAFLD: Guidelines for Referral in NAFLD. Diabetes Care, 38, 1347-1355. https://doi.org/10.2337/dc14-1239
|
[16]
|
Tian, J., Goldstein, J.L. and Brown, M.S. (2016) Insulin Induction of SREBP-1c in Rodent Liver Requires LXRα-C/EBPβ Complex. Proceedings of the National Academy of Sciences of the United States of America, 113, 8182-8187. https://doi.org/10.1073/pnas.1608987113
|
[17]
|
Schmid, A.I., Szendroedi, J., Chmelik, M., Krssak, M., Moser, E. and Roden, M. (2011) Liver ATP Synthesis Is Lower and Relates to Insulin Sensitivity in Patients with Type 2 Diabetes. Diabetes Care, 34, 448-453. https://doi.org/10.2337/dc10-1076
|
[18]
|
Kamagate, A. and Dong, H.H. (2008) FoxO1 Integrates Insulin Signaling to VLDL Production. Cell Cycle, 7, 3162-3170. https://doi.org/10.4161/cc.7.20.6882
|
[19]
|
Kim, D.S., Jackson, A.U., Li, Y.K., Stringham, H.M., Kuusisto, J., Kangas, A.J., et al. (2017) Novel Association of TM6SF2 rs58542926 Genotype with Increased Serum Tyrosine Levels and Decreased apoB-100 Particles in Finns. Journal of Lipid Research, 58, 1471-1481. https://doi.org/10.1194/jlr.P076034
|
[20]
|
Miquilena-Colina, M.E., Lima-Cabello, E., Sanchez-Campos, S., García-Mediavilla, M.V., Fernández-Bermejo, M., Lozano-Rodríguez, T., et al. (2011) Hepatic Fatty Acid Translocase CD36 Upregulation Is Associated with Insulin Resistance, Hyperinsulinaemia and Increased Steatosis in Non-Alcoholic Steatohepatitis and Chronic Hepatitis C. Gut, 60, 1394-1402. https://doi.org/10.1136/gut.2010.222844
|
[21]
|
Sharma, M., Mitnala, S., Vishnubhotla, R.K., Mukherjee, R., Reddy, D.N. and Rao, P.N. (2015) The Riddle of Non-Alcoholic Fatty Liver Disease: Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis. Journal of Clinical and Experimental Hepatology, 5, 147-158. https://doi.org/10.1016/j.jceh.2015.02.002
|
[22]
|
DI Maira, G., Pastore, M. and Marra, F. (2018) Liver Fibrosis in the Context of Non-Alcoholic Steatohepatitis: The Role of Adipokines. Minerva Gastroenterologica e Dietologica, 64, 39-50.
|
[23]
|
Kazankov, K., Jørgensen, S.M.D., Thomsen, K.L., Møller, H.J., Vilstrup, H., George, J., et al. (2019) The Role of Macrophages in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis. Nature Reviews Gastroenterology & Hepatology, 16, 145-159. https://doi.org/10.1038/s41575-018-0082-x
|
[24]
|
Luedde, T., Kaplowitz, N. and Schwabe, R.F. (2014) Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance. Gastroenterology, 147, 765-783.e4. https://doi.org/10.1053/j.gastro.2014.07.018
|
[25]
|
Elkrief, L., Rautou, P.-E., Sarin, S., Valla, D., Paradis, V. and Moreau, R. (2016) Diabetes Mellitus in Patients with Cirrhosis: Clinical Implications and Management. Liver International: Official Journal of the International Association for the Study of the Liver, 36, 936-948. https://doi.org/10.1111/liv.13115
|
[26]
|
Garcia-Compean, D., Jaquez-Quintana, J.O., Gonzalez-Gonzalez, J.A. and Maldonado-Garza, H. (2009) Liver Cirrhosis and Diabetes: Risk Factors, Pathophysiology, Clinical Implications, and Management. World Journal of Gastroenterology, 15, 280-288. https://doi.org/10.3748/wjg.15.280
|
[27]
|
Gangopadhyay, K.K. and Singh, P. (2017) Consensus Statement on Dose Modifications of Antidiabetic Agents in Patients with Hepatic Impairment. Indian Journal of Endocrinology and Metabolism, 21, 341-354. https://doi.org/10.4103/ijem.IJEM_512_16
|
[28]
|
Petrides, A.S. (1994) Liver Disease and Diabetes Mellitus. Diabetes Reviews, 2, 2-18.
|
[29]
|
American Diabetes Association (2019) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes 2019. Diabetes Care, 42, S90-102. https://doi.org/10.2337/dc19-S009
|
[30]
|
Hamed, A.E., Abas, B., Shaltout, I., Esmt, G. and Gomez, R. (2015) Managing Diabetes and Liver Disease Association, Guidelines (Consensus) Development. Journal of Endocrinology, Diabetes & Obesity, 3, 1073.
|
[31]
|
Scheen, A.J. (2014) Pharmacokinetic and Toxicological Considerations for the Treatment of Diabetes in Patients with Liver Disease. Expert Opinion on Drug Metabolism & Toxicology, 10, 839-857. https://doi.org/10.1517/17425255.2014.902444
|
[32]
|
Brackett, C.C. (2010) Clarifying Metformin’s Role and Risks in Liver Dysfunction. Journal of the American Pharmacists Association, 50, 407-410. https://doi.org/10.1331/JAPhA.2010.08090
|
[33]
|
Canadian Diabetes Association (2016) Antihyperglycemic Agents for Use in Type 2 Diabetes. https://guidelines.diabetes.ca/Browse/Chapter13
|
[34]
|
Gliclazide Tablets, Prescribing Information. Actavis UK Ltd., Barnstaple. https://www.medicines.org.uk/emc/product/5883/smpc#gref
|
[35]
|
(2013) Diaßeta (Glyburide) Tablet, Prescribing Information. Sanofi, Bridgewater. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017532Orig1s034lbl.pdf
|
[36]
|
(2013) Amaryl (Glimepiride) Tablet, Prescribing Information. Sanofi, Bridgewater. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020496s027lbl.pdf
|
[37]
|
(2013) Glucotrol (Glipizide) Tablet, Prescribing Information. Pfizer Inc., New York. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/017783s025lbl.pdf
|
[38]
|
Chang, E., Park, C.Y. and Park, S.W. (2013) Role of Thiazolidinediones, Insulin Sensitizers, in Non-Alcoholic Fatty Liver Disease. Journal of Diabetes Investigation, 4, 517-524. https://doi.org/10.1111/jdi.12107
|
[39]
|
Golightly, L.K., Drayna, C.C. and McDermott, M.T. (2012) Comparative Clinical Pharmacokinetics of Dipeptidyl Peptidase-4 Inhibitors. Clinical Pharmacokinetics, 51, 501-514. https://doi.org/10.1007/BF03261927
|
[40]
|
The, Y.L. (2012) Clinical Pharmacokinetics and Pharmacodynamics of Vildagliptin. Clinical Pharmacokinetics, 51, 147-162. https://doi.org/10.2165/11598080-000000000-00000
|
[41]
|
Migoya, E.M., Stevens, C.H., Bergman, A.J., Luo, W.L., Lasseter, K.C., Dilzer, S.C., et al. (2009) Effect of Moderate Hepatic Insufficiency on the Pharmacokinetics of Sitagliptin. Canadian Journal of Clinical Pharmacology, 16, e165-e170.
|
[42]
|
Arase, Y., Suzuki, F., Kobayashi, M., Suzuki, Y., Kawamura, Y., Matsumoto, N., et al. (2011) Efficacy and Safety in Sitagliptin Therapy for Diabetes Complicated by Chronic Liver Disease Caused by Hepatitis C Virus. Hepatology Research, 41, 524-529. https://doi.org/10.1111/j.1872-034X.2011.00798.x
|
[43]
|
Ligueros-Saylan, M., Foley, J.E., Schweizer, A., Couturier, A. and Kothny, W. (2010) An Assessment of Adverse Effects of Vildagliptin versus Comparators on the Liver, the Pancreas, the Immune System, the Skin and in Patients with Impaired Renal Function from a Large Pooled Database of Phase II and III Clinical Trials. Diabetes, Obesity and Metabolism, 12, 495-509. https://doi.org/10.1111/j.1463-1326.2010.01214.x
|
[44]
|
Kalra, S. (2011) Emerging Role of Dipeptidyl Peptidase-IV (DPP-4) Inhibitor Vildagliptin in the Management of Type 2 Diabetes. Journal of the Association of Physicians of India, 59, 237-245.
|
[45]
|
Scheen, A.J. (2015) Pharmacokinetics, Pharmacodynamics, and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clinical Pharmacokinetics, 54, 691-708. https://doi.org/10.1007/s40262-015-0264-4
|
[46]
|
Devineni, D., Curtin, C.R., Marbury, T.C., Smith, W., Vaccaro, N., Wexler, D., et al. (2015) Effect of Hepatic or Renal Impairment on the Pharmacokinetics of Canagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor. Clinical Therapeutics, 37, 610-8.e4. https://doi.org/10.1016/j.clinthera.2014.12.013
|
[47]
|
Kasichayanula, S., Liu, X., Zhang, W., Pfister, M., LaCreta, F.P. and Boulton, D.W. (2011) Influence of Hepatic Impairment on the Pharmacokinetics and Safety Profile of Dapagliflozin: An Open-Label, Parallel-Group, Single-Dose Study. Clinical Therapeutics, 33, 1798-1808. https://doi.org/10.1016/j.clinthera.2011.09.011
|
[48]
|
Zhang, M., Zhang, L., Wu, B., Song, H., An, Z. and Li, S. (2014) Dapagliflozin Treatment for Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Diabetes/Metabolism Research and Reviews, 30, 204-221. https://doi.org/10.1002/dmrr.2479
|
[49]
|
Nigro, S.C., Riche, D.M., Pheng, M. and Baker, W.L. (2013) Canagliflozin, a Novel SGLT2 Inhibitor for the Treatment of Type 2 Diabetes. Annals of Pharmacotherapy, 47, 1301-1311. https://doi.org/10.1177/1060028013503626
|
[50]
|
Scheen, A.J. (2014) Pharmacokinetic and Pharmacodynamic Profile of Empagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor. Clinical Pharmacokinetics, 53, 213-225. https://doi.org/10.1007/s40262-013-0126-x
|
[51]
|
Buse, J.B., Klonoff, D.C., Nielsen, L.L., Guan, X., Bowlus, C.L., Holcombe, J.H., et al. (2007) Metabolic Effects of Two Years of Exenatide Treatment on Diabetes, Obesity, and Hepatic Biomarkers in Patients with Type 2 Diabetes: An Interim Analysis of Data from the Open-Label, Uncontrolled Extension of Three Double-Blind, Placebo-Controlled Trials. Clinical Therapeutics, 29, 139-153. https://doi.org/10.1016/j.clinthera.2007.01.015
|
[52]
|
Ohki, T., Isogawa, A., Iwamoto, M., Ohsugi, M., Yoshida, H., Toda, N., et al. (2012) The Effectiveness of Liraglutide in Non-Alcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone. Scientific World Journal, 2012, Article ID: 496453. https://doi.org/10.1100/2012/496453
|
[53]
|
Tolman, K.G., Fonseca, V., Dalpiaz, A. and Tan, M.H. (2007) Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients with Diabetes and Liver Disease. Diabetes Care, 30, 734-743. https://doi.org/10.2337/dc06-1539
|
[54]
|
Petrides, A.S., Stanley, T., Matthews, D.E., Vogt, C., Bush, A.J. and Lambeth, H. (1998) Insulin Resistance in Cirrhosis: Prolonged Reduction of Hyperinsulinemia Normalizes Insulin Sensitivity. Hepatology, 28, 141-149. https://doi.org/10.1002/hep.510280119
|
[55]
|
Marks, V. and Teale, J.D. (1999) Drug-Induced Hypoglycemia. Endocrinology and Metabolism Clinics of North America, 28, 555-577. https://doi.org/10.1016/S0889-8529(05)70088-8
|
[56]
|
Perseghin, G., Mazzaferro, V., Sereni, L.P., Regalia, E., Benedini, S., Bazzigaluppi, E., et al. (2000) Contribution of Reduced Insulin Sensitivity and Secretion to the Pathogenesis of Hepatogenous Diabetes: Effect of Liver Transplantation. Hepatology, 31, 694-703. https://doi.org/10.1002/hep.510310320
|